CytomX Therapeutics, Inc. Contract with Customer, Liability, Noncurrent
CytomX Therapeutics, Inc. (CTMX) had Contract with Customer, Liability, Noncurrent of $30.62 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Noncurrent $30.62M.
- 2026-03-31: Contract with Customer, Liability, Noncurrent $979.00K.
- 2025-12-31: Contract with Customer, Liability, Noncurrent $1.59M.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $5.54M.
| Period end | Contract with Customer, Liability, Noncurrent | Contract with Customer, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $30.62M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $979.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.59M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $5.54M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $10.24M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $16.21M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $26.86M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $33.56M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $36.71M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $59.74M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $80.05M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $112.26M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $140.87M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $157.13M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $180.06M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $168.33M 10-K · filed 2023-03-27 | $85.12M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $203.91M 10-K · filed 2023-03-27 | $95.86M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $222.09M 10-K · filed 2023-03-27 | $108.79M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $243.94M 10-K/A · filed 2023-03-27 | $125.66M 10-K · filed 2022-03-01 |
| 2021-09-30 | $254.26M 10-K/A · filed 2023-03-27 | $140.77M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $264.09M 10-K/A · filed 2023-03-27 | $158.19M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $267.75M 10-K/A · filed 2023-03-27 | $169.28M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $276.65M 10-K/A · filed 2023-03-27 | $186.26M 10-K · filed 2021-02-24 |
| 2020-09-30 | $202.56M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $221.54M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $236.79M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $178.86M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $187.72M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $197.83M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $197.75M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $225.27M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $236.37M 10-Q · filed 2018-11-06 | |
| 2017-12-31 | $264.70M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |